MRNS logo

Marinus Pharmaceuticals (MRNS) Company Overview

Profile

Full Name:

Marinus Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 31, 2014

Indexes:

Not included

Description:

Marinus Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare neurological disorders. Their main product, ZTALMY, is used to treat seizures associated with a specific condition called CDKL5 deficiency disorder. The company aims to improve the lives of patients with challenging medical needs.

Key Details

Price

$0.55

Annual Revenue

$30.99 M(+21.63% YoY)

Annual EPS

-$2.63(-415.69% YoY)

Annual ROE

-213.02%

Beta

1.28

Events Calendar

Earnings

Next earnings date:

Mar 5, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 5, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sep 23, 2020

Analyst ratings

Recent major analysts updates

Nov 14, 24 HC Wainwright & Co.
Neutral
Nov 14, 24 Cantor Fitzgerald
Overweight
Oct 25, 24 TD Cowen
Hold
Oct 25, 24 RBC Capital
Sector Perform
Oct 25, 24 Jefferies
Hold
Oct 25, 24 HC Wainwright & Co.
Neutral
Oct 25, 24 Cantor Fitzgerald
Overweight
Oct 24, 24 JMP Securities
Market Perform
Oct 24, 24 EF Hutton
Buy
Aug 14, 24 Ladenburg Thalmann
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know
MRNS
zacks.comJanuary 10, 2025

Marinus Pharmaceuticals (MRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
MRNS
businesswire.comDecember 30, 2024

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) to Immedica Pharma AB for $0.55 per share is fair to Marinus shareholders. Halper Sadeh encourages Marinus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Marinus an.

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
MRNS
zacks.comNovember 12, 2024

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago.

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
MRNS
businesswire.comSeptember 20, 2024

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will present an in-depth review of the Company's development program for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead of the Phase 3 TrustTSC trial topline data readout anticipated in the first half of the fourth quarter of 2024.

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
MRNS
businesswire.comAugust 19, 2024

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. Eastern Time in New York and via webcast. The event will feature presentations from Marinus management and key opinion leaders with a focus on the Company's development program for ZTALMY® (ganaxolone) oral suspension CV in.

Marinus Pharmaceuticals, Inc. (MRNS) Q2 2024 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (MRNS) Q2 2024 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (MRNS) Q2 2024 Earnings Call Transcript
MRNS
seekingalpha.comAugust 13, 2024

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Sonya Weigle - Chief People and Investor Relations Officer Scott Braunstein - Chairman and Chief Executive Officer Lisa Lejuwaan - Senior Vice President and Business Unit Lead, Rare Genetic Epilepsy Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - Chief Financial Officer and Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joseph Thome - TD Cowen Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Marc Goodman - Leerink Operator Greetings and welcome to Marinus Pharmaceuticals' Second Quarter Financial Results and Business Update Call.

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates
MRNS
zacks.comAugust 13, 2024

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.61 per share a year ago.

Investors Are Invited To Participate In The Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm
Investors Are Invited To Participate In The Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm
Investors Are Invited To Participate In The Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm
MRNS
accesswire.comAugust 7, 2024

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

MRNS Investors Have Opportunity To Join Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm
MRNS Investors Have Opportunity To Join Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm
MRNS Investors Have Opportunity To Join Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm
MRNS
accesswire.comAugust 6, 2024

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS
MRNS
accesswire.comAugust 5, 2024

NEW YORK, NY / ACCESSWIRE / August 5, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=93921&wire=1 or contact Joseph E. Levi, Esq.

FAQ

  • What is the ticker symbol for Marinus Pharmaceuticals?
  • Does Marinus Pharmaceuticals pay dividends?
  • What sector is Marinus Pharmaceuticals in?
  • What industry is Marinus Pharmaceuticals in?
  • What country is Marinus Pharmaceuticals based in?
  • When did Marinus Pharmaceuticals go public?
  • Is Marinus Pharmaceuticals in the S&P 500?
  • Is Marinus Pharmaceuticals in the NASDAQ 100?
  • Is Marinus Pharmaceuticals in the Dow Jones?
  • When was Marinus Pharmaceuticals's last earnings report?
  • When does Marinus Pharmaceuticals report earnings?
  • Should I buy Marinus Pharmaceuticals stock now?

What is the ticker symbol for Marinus Pharmaceuticals?

The ticker symbol for Marinus Pharmaceuticals is NASDAQ:MRNS

Does Marinus Pharmaceuticals pay dividends?

No, Marinus Pharmaceuticals does not pay dividends

What sector is Marinus Pharmaceuticals in?

Marinus Pharmaceuticals is in the Healthcare sector

What industry is Marinus Pharmaceuticals in?

Marinus Pharmaceuticals is in the Biotechnology industry

What country is Marinus Pharmaceuticals based in?

Marinus Pharmaceuticals is headquartered in United States

When did Marinus Pharmaceuticals go public?

Marinus Pharmaceuticals's initial public offering (IPO) was on July 31, 2014

Is Marinus Pharmaceuticals in the S&P 500?

No, Marinus Pharmaceuticals is not included in the S&P 500 index

Is Marinus Pharmaceuticals in the NASDAQ 100?

No, Marinus Pharmaceuticals is not included in the NASDAQ 100 index

Is Marinus Pharmaceuticals in the Dow Jones?

No, Marinus Pharmaceuticals is not included in the Dow Jones index

When was Marinus Pharmaceuticals's last earnings report?

Marinus Pharmaceuticals's most recent earnings report was on Nov 12, 2024

When does Marinus Pharmaceuticals report earnings?

The next expected earnings date for Marinus Pharmaceuticals is Mar 5, 2025

Should I buy Marinus Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions